
SER Stock Forecast & Price Target
SER Analyst Ratings
Bulls say
Serina Therapeutics Inc is positioned favorably due to its innovative POZ Platform delivery technology, which enhances drug loading control and release precision, addressing market needs in treating neurological diseases and pain. The advancement of pipeline candidates, particularly SER-252, alongside the potential success of SER-270, presents significant upside potential that is currently unaccounted for in the company's valuation assessment. Furthermore, the expanding approval footprint of enFuse suggests a strong likelihood of increased global acceptance for SER-252, which may further enhance Serina Therapeutics’s market position and financial performance in the coming years.
Bears say
Serina Therapeutics reported a consistent net loss of $0.64 per share, indicating ongoing financial challenges for the company. The outlook is further clouded by significant risks, including the potential inability to advance their lead candidate, SER-252, through clinical development, secure necessary regulatory approvals, and achieve anticipated market uptake due to competition and other dynamics. Additionally, there are concerns regarding future partnership opportunities and the risk of dilution, with full-year 2025 net loss estimates increasing substantially to $2.01 from an original forecast of $0.36 per share.
This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
SER Analyst Forecast & Price Prediction
Start investing in SER
Order type
Buy in
Order amount
Est. shares
0 shares